Wegovy and Zepbound makers Novo Nordisk and Eli Lilly faced pressure.
News
Weight Loss Drug Stocks Novo Nordisk, Eli Lilly Slump Below Key Levels
Licensing
11:51 AM ET 07/31/2026
Weight loss drug stock leaders slumped on Friday amid updates and ahead of earnings. NVO stock sank under a buy point on trial results. LLY stock dived below support with earnings due next week. Updating the closely watched ZEUS phase 3 clinical trial, Denmark's Novo Nordisk (NVO) announced overnight that its experimental cardiovascular drug, ziltivekimab — to treat heart disease,…
Novo Nordisk stock fell as much as 10% Monday after it said its next-generation weight loss drug didn't meet its primary target.
The weight-loss drug wars reached a new level of intensity Tuesday as Novo Nordisk sued Eli Lilly, accusing its arch-rival of…
Danish drugmaker jumps by about £9bn as trial shows ‘significant weight loss’ with tablet version of Wegovy
The early data is a boost to the Danish drugmaker's hopes of winning back more market share from Eli Lilly this year in the…
The results could reinforce Eli Lilly and Novo Nordisk's dominance in the booming market for weight loss and diabetes drugs.
Novo Nordisk claims Eli Lilly compared peak doses of Zepbound against outdated, lower doses of Wegovy to advertise a 50-pound…
